share_log

Transcode Therapeutics | 424B5: Prospectus

Transcode Therapeutics | 424B5: Prospectus

Transcode Therapeutics | 424B5：募资说明书
美股SEC公告 ·  07/22 16:13

Moomoo AI 已提取核心信息

TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.
TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.
TransCode Therapeutics, Inc.宣布发行普通股、可预付款购买普通股的认股权证和可通过预付款购买得到的普通股份。 该发行在《证券法》第424（b）（5）条规定的招股说明书补充中详细说明。日期为2024年7月22日的招股说明书概述了发行的条款，包括股票和可预付款认股权证的购买价格，可预付款认股权证的即时行权以及尚未建立预付款认股权证交易市场。TransCode已聘请ThinkEquity LLC作为该发行的独家配售代理，该发行是在最佳努力的基础上进行，无最低发行要求。所得款项将用于产品开发活动、临床试验、营运资金和其他一般公司用途。该发行预计于2024年7月左右结束，须符合惯例的交割条件。
TransCode Therapeutics, Inc.宣布发行普通股、可预付款购买普通股的认股权证和可通过预付款购买得到的普通股份。 该发行在《证券法》第424（b）（5）条规定的招股说明书补充中详细说明。日期为2024年7月22日的招股说明书概述了发行的条款，包括股票和可预付款认股权证的购买价格，可预付款认股权证的即时行权以及尚未建立预付款认股权证交易市场。TransCode已聘请ThinkEquity LLC作为该发行的独家配售代理，该发行是在最佳努力的基础上进行，无最低发行要求。所得款项将用于产品开发活动、临床试验、营运资金和其他一般公司用途。该发行预计于2024年7月左右结束，须符合惯例的交割条件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间